Use of magnetic resonance imaging to support dose selection in a phase II trial of baricitinib combined with conventional synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis

類似資料

• Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
  著者:: Peterfy, C, 等
  出版事項: (2012)
• Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis
  著者:: Keystone, EC, 等
  出版事項: (2017)
• 24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
  著者:: Genovese, M, 等
  出版事項: (2012)
• Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
  著者:: Keystone, E, 等
  出版事項: (2015)
• Baricitinib versus placebo or adalimumab in rheumatoid arthritis
  著者:: Taylor, P, 等
  出版事項: (2017)